3 results match your criteria: "Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI)[Affiliation]"
Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam.
Antimicrob Agents Chemother
November 2021
Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Australia.
The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine in Vietnam justifies the need to evaluate alternative artemisinin-based combination therapies. Between July 2018 and October 2019, a single-arm trial of pyronaridine-artesunate (Pyramax, PA) was conducted in Dak Nong province, Vietnam. PA (3-day course) was administered to adults and children infected with P.
View Article and Find Full Text PDFEfficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Monkey-Human Malaria Model.
Antimicrob Agents Chemother
February 2020
Department of Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Queensland, Australia
Nonimmune monkeys infected with and were cured of their infections when treated with a single oral dose of 5 mg/kg and 10 mg/kg of the 2-aminomethylphenol, JPC-3210, respectively. Corresponding mean blood elimination half-lives of JPC-3210 were lengthy at 19.1 days and 20.
View Article and Find Full Text PDFA review of the WHO malaria rapid diagnostic test product testing programme (2008-2018): performance, procurement and policy.
Malar J
December 2019
Foundation for Innovative New Diagnostics (FIND), Campus Biotech, Building B, Level 0, Chemin des Mines 9, 1202, Geneva, Switzerland.
Article Synopsis
- * The program tested 332 RDT products against Plasmodium falciparum and Plasmodium vivax, utilizing measures like panel detection score, false positive rate, and invalid rate, resulting in an increase of products meeting performance criteria from 26.8% to 79.4% over multiple testing rounds.
- * This independent evaluation improved transparency in the market, allowing healthcare providers to make informed decisions on malaria diagnosis and treatment, ultimately leading to a greater acceptance of RDTs in case management